Keynote webinar | Spotlight on cardio-oncology
Cancer-related cardiovascular sequelae increase the risks of morbidity and mortality, and threaten the chances patients experiencing healthy cancer survivorship. New ESC guidelines, focused on the intersectionality of these specialties, underpin this webinar explaining how best to care for cancer patients at risk of cardiovascular complications.
You must have an account and be logged in to access the recording of this webinar. The on-demand version is not accredited.
No account yet? Register here for free
Agenda
What we should all know about ESC guidelines on cardio-oncology
Dr. Teresa López Fernández
Immune checkpoint inhibitor-associated myocarditis
Prof. Lorenz Lehmann
Biomarkers in cardio-oncology
Prof. Rudolf de Boer
Panel discussion with all experts
Faculty
Prof. Rudolf de Boer
Clinical Cardiologist and Professor of Translational Cardiology at the University Medical Center Groningen, The Netherlands
Prof. Lorenz Lehmann
Professor of Cardiology, Heidelberg University Hospital, Heidelberg, Germany
Dr. Teresa López Fernández
Consultant Cardiologist, University Hospital La Paz, Madrid, Spain
Learning objectives
After participating in this program, learners will be able to:
- Apply the new ESC cardio-oncology guidelines to treatment of cancer patients with cardiovascular risks
- Identify and appraise the risks of cardiological outcomes in patients receiving immune-checkpoint inhibitor therapy
- Identify and utilize biomarkers as part of long-term follow-up of cardiovascular risks in cancer patients
Faculty information and disclosures
Prof. Rudolf de Boer
Prof. de Boer is a Clinical Cardiologist, a Professor of Translational Cardiology, and the Director of the Experimental Cardiology at the University Medical Center Groningen, the Netherlands.
Disclosures
- Grant/research support: AstraZeneca, Abbott, Boehringer Ingelheim, Cardio Pharmaceuticals GmbH, Ionis Pharmaceuticals Inc, Novo Nordisk, Roche
- Speaker’s Bureau: Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, Roche
Prof. Lorenz Lehmann
Prof. Lorenz Lehmann is a Clinical Cardiologist, a Professor of Cardiology and the Head of the Institute of Cardio-Oncology as well as the Special Outpatient Clinic for Cardio-Oncology at the Heidelberg University Hospital.
Disclosures
- Honoraria/consultation fees: Daiichi Sankyo, Senaca, AstraZeneca, Servier
- Speaker’s Bureau: Novartis, MSD
Dr. Teresa López Fernández
Dr. López Fernández leads the Cardio-Oncology Unit at University Hospital La Paz, Madrid, where she specializes in cardiac imaging.
Disclosures
- Honoraria/consultation fees: Philips, Myocardial Solutions
- Speaker’s Bureau: Janssen, Daiichi Sankyo, AstraZeneca, Beigene
Moderators
Dr. Jane Godsland
Clinical Director, Springer Medicine, Springer Healthcare, London, United Kingdom
Disclosures
Dr. Erik Heintz
Editor-in-Chief SpringerMedizin.de, Springer Medizin Verlag GmbH, Munich, Germany
Disclosures
Stay tuned for more webinars from Springer Medicine
Receive email notifications about the broadcast dates of future webinars by subscribing to "Springer Medicine Updates"
No account yet? Click here to register for free
